Altre lingue Caribou Biosciences, Inc.

Azioni

CRBU

US1420381089

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
3,68 ^USD	+1,38%		-4,42%	-35,78%

05/04	Aggiornamento settoriale: i titoli del settore sanitario sono in rialzo prima della campanella di venerdì	MT
04/04	Caribou ottiene l'autorizzazione della FDA per i test di fase 1 della terapia cellulare CB-010 nei pazienti affetti da lupus	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Caribou Biosciences to Participate in Upcoming Investor Conferences	01/05
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Caribou Biosciences : CB-010 ANTLER Case Study iwCAR-T 2024	23/04
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15/04
Caribou Biosciences : CB-012 IND-enabling preclinical data AACR 2024	09/04
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	04/04
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04/04
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04/04
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	25/03
50 valores para invertir en IA, salud, movilidad y energía	25/03
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	23/03
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	22/03
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	22/03
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	11/03
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting	05/03
Caribou Biosciences to Participate in Upcoming Investor Conferences	15/02
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024	07/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Caribou Biosciences, Inc.

Azioni

CRBU

US1420381089

Altre lingue

Filtri